Akari Completes Merger with Peak Bio Successfully
14 Nov 2024 //
GLOBENEWSWIRE
Akari Therapeutics Shareholder Approval for Peak Bio Merger
08 Nov 2024 //
GLOBENEWSWIRE
Akari Therapeutics Announces Effectiveness of Form S-4 and On Nov 7
15 Oct 2024 //
GLOBENEWSWIRE
Akari Therapeutics Reports Q2 2024 Financial Results And Highlights
19 Aug 2024 //
GLOBENEWSWIRE
Akari Therapeutics Reports Q1 2024 Financials, Highlights
16 May 2024 //
GLOBENEWSWIRE
Akari, Peak Bio Plan For Post-Merger Pipeline Prioritization
01 May 2024 //
GLOBENEWSWIRE
Akari Therapeutics and Peak Bio Announce Definitive Agreement
05 Mar 2024 //
GLOBENEWSWIRE
Peak Bio Awarded Patent with Coverage for Thailanstatin-ADC platform technology
04 Jan 2024 //
GLOBENEWSWIRE
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1
19 Sep 2023 //
GLOBENEWSWIRE
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
31 Aug 2023 //
GLOBENEWSWIRE
Peak Bio, Inc. Announces Up-listing to OTCQB Market
31 Aug 2023 //
GLOBENEWSWIRE
Peak Bio, Inc. Announces its Application to Uplist to the OTCQB Venture Market
29 Aug 2023 //
GLOBENEWSWIRE
Peak Bio Announces Amendment and Continued Access to Equity Line of $100M
24 Aug 2023 //
GLOBENEWSWIRE
Peak Bio Presents Data Highlighting Potential of Differentiated Trop2 PH1 ADC
23 Aug 2023 //
GLOBENEWSWIRE